JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology - PubMed
6 days ago
- #GLP-1 receptor agonists
- #dermatology
- #inflammatory skin diseases
- GLP-1 receptor agonists (GLP-1RAs) are primarily used for type 2 diabetes and obesity, offering benefits like improved glycemic control and weight loss.
- Emerging evidence suggests GLP-1RAs may have anti-inflammatory and immunomodulatory effects, potentially benefiting chronic inflammatory skin diseases such as psoriasis and hidradenitis suppurativa (HS).
- Reported dermatologic benefits include reduced Psoriasis Area and Severity Index scores, improved HS symptoms, and better wound-healing outcomes.
- The benefits may stem from both direct immunomodulation and indirect metabolic effects like weight loss and reduced systemic inflammation.
- Current evidence is limited by small sample sizes, variability in agents/dosing, and confounding factors like comorbid conditions and concurrent therapies.
- Potential adverse effects include gastrointestinal intolerance, biliary disease, retinopathy risk, and dermatologic reactions (e.g., pruritus, drug eruptions, alopecia, acne).
- Larger, long-term randomized trials are needed to confirm efficacy, mechanisms, and safety in dermatologic applications.